A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05297045
• Other study ID #: RGT001-075_01-201
• Status: Terminated
• Phase: Phase 2
• Start date: March 29, 2022
• Est. completion date: May 30, 2023

Study information

• Verified date: November 2023
• Source: Regor Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Diagnosed with type 2 diabetes that has been treated with lifestyle modification and a stable dose of metformin =1000 mg/day (or maximum tolerated dose) for at least 3 months at the time of Screening
• Screening HbA1c 7.0-10.5%
• Male or female, age 18-75 years
• Screening BMI 24.5 - 40 kg/m2
• Either surgically sterile, abstinent, or willing to use a highly effective method of contraception for the entirety of the study, and not be pregnant or lactating if a woman of child-bearing potential

Exclusion Criteria:

• Has received within the preceding 3 months prior to Screening, another approved or investigational oral or injectable antidiabetic medication (including, but not limited to sulfonylureas, dipeptidyl peptidase-4 inhibitor [DPP-4i], sodium-glucose cotransport 2 inhibitors, alphaglucosidase inhibitors, meglitinides, thiazolidinediones) or insulin in addition to metformin therapy
• Has active GI disease including acute or chronic pancreatitis, severe gastroparesis or chronic malabsorption, inflammatory bowel disease, symptomatic gallbladder or biliary disease, known unstable liver disease, a diagnosis of fibrotic nonalcoholic steatohepatitis (NASH), Gilbert's syndrome, or obvious clinical signs or symptoms of liver disease including chronic active hepatitis B or C, or primary biliary cirrhosis, or elevated alanine aminotransferase (ALT) levels at Screening
• Has any history of myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary therapeutic intervention, transient ischemic attack, stroke, or decompensated congestive heart failure within previous 6 months prior to Screening
• Has an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2
• Has active proliferative diabetic retinopathy or macular edema
• Has a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid cancer
• Has an active or untreated malignancy or has been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years prior to screening
• Has evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
• Has had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening
• Has been treated or plan to be treated with drugs or devices or surgery that promote weight loss within 3 months prior to screening

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• RGT001-075
Oral GLP1 Receptor Agonist

Other:
• Placebo
Placebo comparator

Locations

Country	Name	City	State
United States	Axon Clinical Research	Doral	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Regor Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Change in mean body weight (absolute and %) from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Change in body mass index from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Change in waist circumference from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population		up to 16 weeks
Secondary	Percentages of patients achieving HbA1c <6.0%, <6.5%, and/or <7.0%		up to 16 weeks
Secondary	Percentages of patients achieving =5% and/or =10% greater body weight loss		up to 16 weeks
Secondary	Incidence of treatment-emergent adverse events (TEAE)s, serious adverse events (SAE)s, deaths, and adverse events (AE)s leading to study discontinuation		up to 16 weeks
Secondary	Vital signs - Systolic blood pressure (mmHg) absolute change from baseline		up to 16 weeks
Secondary	Vital signs - Diastolic blood pressure (mmHg) absolute change from baseline		up to 16 weeks
Secondary	Vital signs - Heart rate (beats/minute) absolute change from baseline		up to 16 weeks
Secondary	Vital signs - Body weight (kg) absolute and percent change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - complete blood count absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum sodium absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum potassium absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum total bilirubin absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum direct bilirubin absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum alkaline phosphatase absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum alanine aminotransferase absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum aspartate aminotransferase absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum blood urea nitrogen absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum creatinine absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum uric acid absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum calcium absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum lipase absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum amylase absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - eGFR (calculated) absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - fasting serum glucose absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum albumin absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum total protein absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - fasting serum total cholesterol absolute change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - fasting serum triglycerides absolute and percent change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - fasting serum HDL-C absolute and percent change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - fasting serum LDL-C absolute and percent change from baseline		up to 16 weeks
Secondary	Safety clinical laboratories - serum calcitonin absolute change from screening		up to 16 weeks
Secondary	ECG interval change from baseline absolute and categorical outliers >450ms		up to 16 weeks
Secondary	Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events		up to 16 weeks